AstraZeneca (AZNS) Stock Overview
A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
AZNS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
AstraZeneca PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£1,789.00 |
| 52 Week High | UK£1,903.00 |
| 52 Week Low | UK£1,233.75 |
| Beta | 0.23 |
| 1 Month Change | -0.28% |
| 3 Month Change | 7.27% |
| 1 Year Change | n/a |
| 3 Year Change | 30.20% |
| 5 Year Change | 111.97% |
| Change since IPO | 504.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| AZNS | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -4.8% | -0.7% | -0.6% |
| 1Y | n/a | 19.0% | 19.0% |
Return vs Industry: Insufficient data to determine how AZNS performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how AZNS performed against the UK Market.
Price Volatility
| AZNS volatility | |
|---|---|
| AZNS Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in GB Market | 11.2% |
| 10% least volatile stocks in GB Market | 2.8% |
Stable Share Price: AZNS has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine AZNS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 96,100 | Pascal Claude Soriot | www.astrazeneca.com |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines.
AstraZeneca PLC Fundamentals Summary
| AZNS fundamental statistics | |
|---|---|
| Market cap | SEK 2.79t |
| Earnings (TTM) | SEK 96.76b |
| Revenue (TTM) | SEK 555.86b |
Is AZNS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AZNS income statement (TTM) | |
|---|---|
| Revenue | US$58.74b |
| Cost of Revenue | US$10.75b |
| Gross Profit | US$47.99b |
| Other Expenses | US$37.77b |
| Earnings | US$10.23b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 29, 2026
| Earnings per share (EPS) | 6.59 |
| Gross Margin | 81.71% |
| Net Profit Margin | 17.41% |
| Debt/Equity Ratio | 57.3% |
How did AZNS perform over the long term?
See historical performance and comparisonDividends
Does AZNS pay a reliable dividends?
See AZNS dividend history and benchmarks| AstraZeneca dividend dates | |
|---|---|
| Ex Dividend Date | Feb 19 2026 |
| Dividend Pay Date | Mar 23 2026 |
| Days until Ex dividend | 24 days |
| Days until Dividend pay date | 8 days |
Does AZNS pay a reliable dividends?
See AZNS dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/13 14:10 |
| End of Day Share Price | 2026/03/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AstraZeneca PLC is covered by 58 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| John Eade | Argus Research Company |
| Odile Rundquist | Baader Helvea Equity Research |